Generated by AI
Ardelyx Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for gastrointestinal and cardiorenal diseases. The company’s current portfolio centers on tenapanor-based therapies, including IBSRELA for adults with irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx also works on therapies for related metabolic and kidney disorders, using its gut-targeted science platform to address conditions that often have limited treatment options. Headquartered in Waltham, Massachusetts, and founded in 2007, Ardelyx serves patients in the United States through direct commercialization and supports broader reach through select partnerships. The company operates in the biotechnology and specialty pharmaceuticals markets, where it contributes prescription treatments designed for chronic, specialist-managed conditions.
Website400 Fifth Avenue
Waltham, MA, 02451
United States
The latest articles about ARDX.
Ardelyx has given long term holders a very different ride from what the recent slump suggests, with a strong multi year return sitting beside a sharp pullback this year. That mix of outcomes puts the spotlight on one thing for anyone looking at the stock today: whether the current share price is adequately backed by the company’s sales. Over the past 5 years, Ardelyx has delivered a 156.8% gain, which makes the current drawdown more important for judging how much of that share price move its...
Ardelyx (ARDX) just paired fresh third quarter 2026 results with progress in its IBSRELA pipeline, giving investors new numbers on current operations alongside an update on its late stage ACCEL trial. That progress has arrived against a tougher tape for Ardelyx, with the share price down 38.3% over the past 90 days and year to date off 50.7%, even though the 5 year total shareholder return is still positive at 156.8%. This shows that long term holders have seen gains, while recent momentum...
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Feb 23's posts. Generated by AI.
Summary of Oct 15's posts. Generated by AI.
Investors talking about ARDX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.